Cleerly ISCHEMIA vs WellDoc BlueStar

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Cleerly
VS
by WellDoc

AI Verdict

Cleerly ISCHEMIA is an AI-powered diagnostic tool for non-invasively detecting coronary artery ischemia from CCTA scans, primarily aiding physicians in diagnosis and treatment planning. In contrast, WellDoc BlueStar is an AI-driven digital health solution focused on chronic disease management, offering personalized coaching and insights for patients with conditions like diabetes, hypertension, and heart failure. While both operate within cardiology, Cleerly focuses on diagnostic imaging analysis, whereas WellDoc emphasizes patient engagement and chronic condition management.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you need a non-invasive, AI-powered diagnostic tool to assess the likelihood of coronary artery ischemia and characterize coronary plaque based on CCTA scans. It is ideal for physicians seeking detailed vessel-level insights and 3D models to inform personalized diagnosis and treatment planning for heart disease.

View Cleerly ISCHEMIA →

Choose WellDoc BlueStar if…

Choose WellDoc BlueStar if you require an AI-powered digital health solution for the ongoing management of chronic conditions like diabetes, hypertension, and heart failure. This tool excels at providing personalized coaching, integrating with connected devices, and offering real-time feedback to empower patients in their self-management journey.

View WellDoc BlueStar →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cleerly ISCHEMIA WellDoc BlueStar
Pricing Contact for details Enterprise pricing; paid by health plans, health systems, or employers.
Deployment Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) Mobile app (iOS, Android) and web-based platform
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

WellDoc BlueStar

WellDoc BlueStar is designed as a mobile app and web platform for patient-facing chronic disease management, offering personalized coaching and data logging. Its focus on accessibility and ease of use for patients managing their conditions daily makes it highly usable for its target audience. Cleerly ISCHEMIA, while offering interactive web-based reports for clinicians, is a specialized diagnostic tool for complex CCTA analysis.

Clinical Value

Cleerly ISCHEMIA

Cleerly ISCHEMIA provides critical, non-invasive diagnostic information for coronary artery disease by analyzing CCTA scans to determine the likelihood of ischemia and characterize coronary plaque. This directly informs immediate treatment pathways and can guide interventional decisions, potentially reducing the need for more invasive procedures. WellDoc BlueStar offers significant value in long-term chronic disease management, but Cleerly's impact on precise diagnosis for a life-threatening condition is arguably more acute and foundational.

Pricing & Value

Tie

Both tools employ opaque pricing models that require direct consultation, making a direct comparison of their cost-effectiveness or value proposition impossible without specific financial data. Cleerly ISCHEMIA's pricing varies by provider, while WellDoc BlueStar uses an enterprise pricing model for health plans, systems, or employers. Their value propositions are also distinct, with Tool A focusing on diagnostic precision and Tool B on chronic condition management.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and having Business Associate Agreements (BAAs) in place. Cleerly ISCHEMIA offers robust integration with radiology workflows via API and secure data transfer. WellDoc BlueStar provides comprehensive care team portals and SMARTVisit reports, supporting broad deployment for chronic disease management across health systems.

Innovation

Cleerly ISCHEMIA

Cleerly ISCHEMIA's ability to non-invasively estimate fractional flow reserve (FFR) and provide detailed coronary plaque characterization from CCTA scans represents a significant innovation in cardiac diagnostics. This technology offers insights previously requiring more invasive procedures, potentially changing clinical pathways. While WellDoc BlueStar's personalized multi-condition coaching is valuable, AI-driven coaching for chronic conditions is a more established area.

Support & Docs

WellDoc BlueStar

WellDoc BlueStar provides readily accessible customer care for its patient-facing mobile application, offering assistance with account management, app functionality, and troubleshooting during business hours. Cleerly also offers technical support for clinicians and guidance for referring providers during business hours. However, WellDoc's explicit focus on direct user support for a broader patient audience gives it an edge in this dimension for its primary users.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cleerly ISCHEMIA WellDoc BlueStar
Tool Name Cleerly ISCHEMIA WellDoc BlueStar
Primary Use Case Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. Digital health solution for chronic disease management, offering personalized coaching and insights for conditions like diabetes, hypertension, and heart failure.
Company Cleerly WellDoc
Primary Categories Cardiology AI, Radiology & Imaging AI Cardiology AI, Endocrinology & Metabolic AI, Patient Engagement & Education
Supported Specialties Cardiology, Radiology Cardiology, Endocrinology, Internal Medicine
Key Feature Example AI-enabled CCTA analysis AI-driven personalized coaching

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and WellDoc BlueStar.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cleerly ISCHEMIA analyzes CCTA scans to provide non-invasive, vessel-level ischemia likelihood and coronary plaque characterization, directly aiding physicians in personalized diagnosis and treatment planning for heart disease. Its comprehensive interactive web-based reports and 3D digital models are designed to enhance the interpretation process and streamline reporting through integration with PowerScribe via API.
WellDoc BlueStar provides AI-driven personalized coaching and real-time feedback directly to patients, supporting self-management of conditions like diabetes, hypertension, and heart failure. Physicians utilize a Care team portal and SMARTVisit reports to review patient data, monitor progress, and inform clinical decisions during appointments.
Cleerly ISCHEMIA offers integration with PowerScribe via API, which streamlines the transfer of its AI-enabled CCTA analysis results into radiology reporting workflows. This allows for efficient incorporation of detailed findings like FFR estimation and stenosis severity into patient records, reducing manual data entry and transcription errors.
WellDoc BlueStar's Care team portal and SMARTVisit reports are designed to summarize patient data from connected devices and logged information, providing actionable insights. This aims to facilitate efficient review of patient progress and inform clinical decisions, with integration into the EHR workflow simplifying the process of connecting patients with their care team.
Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding in personalized diagnosis and treatment planning. Its ability to determine likely ischemia has been validated through multiple clinical trials with invasive FFR as the gold standard, demonstrating high diagnostic accuracy.
WellDoc BlueStar supports multi-condition management, including diabetes, hypertension, heart failure, and weight management, and integrates with various connected devices, making it adaptable for diverse patient needs. Its enterprise pricing model and mobile app deployment suggest scalability across large organizations and varied patient demographics, with proven increased patient engagement when recommended by a medical provider.
Beyond HIPAA compliance, WellDoc BlueStar employs a robust, multi-layered security strategy, including data encryption in transit and at rest using AES-256, secure communication via Transport Layer Security protocols, and implemented Intrusion Detection Systems. It also holds HITRUST r2 and SOC2 Type 2 certifications, demonstrating continuous and effective operation of controls over security, availability, and confidentiality of user data.
AI Tool Finder
AI-powered search. Results may not be comprehensive.